Michael Fons
Corporate Officer/Principal bei University of Texas Medical Branch
Profil
Michael Fons is currently working as an Adjunct Associate Professor at the University of Texas Medical Branch.
Previously, he worked as an Executive Director-Business Development at Vical, Inc. from 2002 to 2004 and as a Vice President-Corporate Development at Inovio Pharmaceuticals, Inc.
Aktive Positionen von Michael Fons
| Unternehmen | Position | Beginn |
|---|---|---|
| University of Texas Medical Branch | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Michael Fons
| Unternehmen | Position | Ende |
|---|---|---|
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01.01.2004 |
| INOVIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
